NEW YORK (GenomeWeb) — Cancer diagnostics firm Precipio said today that it expects to report a 213 percent increase in its second quarter revenues on strong demand for its pathology services.

On a preliminary basis, Precipio's revenues for the three-month period ended June 30 were $815,000 compared with $260,000 in the year-ago quarter. The firm said sales of its pathology services were the primary driver of the increase, in part reflecting the effect of its recently expanded sales team.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.